NASDAQ:IMVT - Immunovant Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $47.75
  • Forecasted Upside: -2.33 %
  • Number of Analysts: 16
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 16 Buy Ratings
  • 0 Strong Buy Ratings
$48.89
▲ +0.22 (0.45%)
1 month | 3 months | 12 months
Get New Immunovant Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMVT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMVT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$47.75
▼ -2.33% Downside Potential
This price target is based on 16 analysts offering 12 month price targets for Immunovant in the last 3 months. The average price target is $47.75, with a high forecast of $64.00 and a low forecast of $27.00. The average price target represents a -2.33% upside from the last price of $48.89.
Buy
The current consensus among 16 contributing investment analysts is to buy stock in Immunovant.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2020
  • 0 strong buy ratings
  • 15 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 16 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/26/2020

Latest Recommendations

  • 0 strong buy ratings
  • 16 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/13/2020TruistBoost Price Target$52.00 ➝ $62.00Medium
i
11/13/2020Robert W. BairdBoost Price TargetOutperform$47.00 ➝ $64.00Medium
i
11/13/2020HC WainwrightBoost Price TargetBuy$40.00 ➝ $54.00High
i
Rating by D. Tsao at HC Wainwright
11/13/2020SVB LeerinkBoost Price TargetOutperform$39.00 ➝ $52.00High
i
11/12/2020Chardan CapitalBoost Price Target$45.00 ➝ $60.00High
i
Rating by Gbola Amusa at Chardan Capital
10/28/2020UBS GroupInitiated CoverageBuy$61.00Medium
i
10/12/2020GuggenheimInitiated CoverageBuy$63.00Medium
i
10/7/2020Stifel NicolausInitiated CoverageBuy$46.00Medium
i
10/6/2020Lifesci CapitalReiterated RatingOutperformHigh
i
Rating by S. Slutsky at Lifesci Capital
10/2/2020CSFBInitiated CoverageOutperform$49.00High
i
10/2/2020Credit Suisse GroupInitiated CoverageOutperform$49.00High
i
8/26/2020TruistBoost Price Target$36.00 ➝ $52.00Low
i
8/26/2020HC WainwrightReiterated RatingBuy$34.00 ➝ $40.00High
i
Rating by D. Tsao at HC Wainwright
8/25/2020Robert W. BairdBoost Price TargetOutperform$31.00 ➝ $47.00Medium
i
8/25/2020Chardan CapitalBoost Price TargetPositive ➝ Buy$35.00 ➝ $45.00Medium
i
Rating by Gbola Amusa at Chardan Capital
8/24/2020Raymond JamesInitiated CoverageOutperform$35.00High
i
8/20/2020SVB LeerinkBoost Price TargetOutperform ➝ Outperform$26.00 ➝ $34.00Medium
i
Rating by T. Smith at SVB Leerink LLC
8/13/2020Chardan CapitalBoost Price TargetBuy$30.00 ➝ $35.00High
i
Rating by G. Amusa at Chardan Capital
8/5/2020Ci CapitalReiterated RatingBuy$32.00Medium
i
7/29/2020HC WainwrightInitiated CoverageBuy$34.00Medium
i
Rating by D. Tsao at HC Wainwright
6/18/2020SunTrust BanksUpgradeBuyHigh
i
Rating by Robyn Karnauskas at SunTrust Banks, Inc.
6/17/2020SunTrust BanksBoost Price Target$24.00 ➝ $36.00Low
i
Rating by Robyn Karnauskas at SunTrust Banks, Inc.
5/29/2020NomuraBoost Price TargetBuy$27.00 ➝ $37.00High
i
5/29/2020Nomura InstinetBoost Price TargetBuy$27.00 ➝ $37.00High
i
3/4/2020Nomura SecuritiesReiterated RatingBuy$27.00Medium
i
Rating by Christopher Marai at Nomura Securities
2/24/2020SVB LeerinkInitiated CoverageOutperform$24.00High
i
Rating by T. Smith at SVB Leerink LLC
2/17/2020Chardan CapitalReiterated RatingBuyMedium
i
Rating by G. Amusa at Chardan Capital
2/4/2020Nomura SecuritiesInitiated CoverageBuy$27.00High
i
Rating by Christopher Marai at Nomura Securities
1/10/2020SunTrust BanksInitiated CoverageBuy$24.00High
i
1/9/2020Chardan CapitalInitiated CoverageBuy$30.00High
i
1/7/2020Robert W. BairdInitiated CoverageOutperform$21.00Medium
i
(Data available from 11/26/2015 forward)
Immunovant logo
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Read More

Today's Range

Now: $48.89
$48.31
$49.50

50 Day Range

MA: $45.41
$38.80
$52.71

52 Week Range

Now: $48.89
$8.34
$53.75

Volume

251,565 shs

Average Volume

352,164 shs

Market Capitalization

$4.79 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A